Researchers are working hard night and day to find new drugs that will inhibit the growth of cancerous cells. In the United States, that research seems to be stymied by some of the rules and regulations imposed by the FDA and the government in general. Live tests take so long to be implemented that breakthroughs are few and far between. That is not to say that good work is not being done; it is just that the clock for a lot of people who are diagnosed with cancer have a small threshold of time for them and it would be too late.
One study that was published in the journal “Cancer Cell” relates that researchers tested the effects of a drug known only as ONO1910 on the growth of tumors. The results were indeed very promising and the researcher responsible for this discovery is E. Premkumar Reddy, PhD, of the Temple University School of Medicine. This is a great breakthrough for those who have cancer and the fact that it will work in conjunction with other known cancer drugs is a bonus. The drug blocks the invasion and then it blocks the new blood vessels from forming that would provide the sustenance needed for the cancer cells to grow.
At the University of Illinois, a 24-member research team that had people from Taiwan, Europe, and Japan engineered an anti-cancer agent that is fully 200 times more active in the killing of tumor cells than other drugs of this ilk. Developers have been on the trail of inhibitor drugs for quite a few years. Until now, the program has met with only limited success. Biosphosphonates have been found to act on the enzymes. The enzymes that this drug inhibits are showing a remarkable result in the act of killing cancer cells. The drug biphosphonates and zoledronate has proven successful for women in the premenopausal stage.
A scientist at the Hiroshima University, Tadahiko Kubo then found that the drug known as BPH-715 actually killed cancer cells in mice. Another scientist from abroad at the Leiden University in the Netherlands named Socrates Papapoulous found that unlike other drugs, this one did not readily attach to the bone.
Gleevec is a drug that gained approval in 2001. It is being used to treat chronic myeloid leukemia or CML as it is commonly referred to. It has shown great promise because those treated with this drug went into remission 84% of the time. This is great news for the millions of people with cancer. The drug Avastin has been approved for use in chemotherapy and since its inception, users have a survival rate of 54% for colorectal cancers.
The advances in drug therapy and the search for inhibitors will continue. The researchers are making leaps where yesterday they were only crawling along. Will cancer be cured in this lifetime no one truly knows? What we do know is that we will fight it tooth and nail all the way.